Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Weinstock

Showing results (141-150 of 172) with videos related to

Pageof 18
Sort By:
Nature Medicine|December 9, 2014
Mutations in G protein β subunits promote transformation and kinase inhibitor resistanceAkinori Yoda, Guillaume Adelmant, Jerome Tamburini, et al.
Genes & Development|March 18, 2022
A distinct core regulatory module enforces oncogene expression in KMT2A-rearranged leukemiaTaku Harada, Yaser Heshmati, Jérémie Kalfon, et al.
Nature Cancer|September 18, 2023
PD-1 instructs a tumor-suppressive metabolic program that restricts glycolysis and restrains AP-1 activity in T cell lymphomaTim Wartewig, Jay Daniels, Miriam Schulz, et al.
The Journal of Experimental Medicine|January 25, 2012
Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibitionOliver Weigert, Andrew A Lane, Liat Bird, et al.
Blood Advances|March 19, 2026
Live-cell Pick-Seq (LiP-Seq): Interrogating ultra-rare mantle cell lymphoma persistent cells after CART19 therapyRan Xu, Gongwei Wu, Siobhan Rice, et al.
Science Translational Medicine|June 28, 2023
Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphomaCristina Mastini, Marco Campisi, Enrico Patrucco, et al.
Plos One|July 5, 2013
Gauging NOTCH1 Activation in Cancer Using ImmunohistochemistryMichael J Kluk, Todd Ashworth, Hongfang Wang, et al.
Cancer Discovery|October 7, 2021
Sex-Biased <i>ZRSR2</i> Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and ApoptosisKatsuhiro Togami, Sun Sook Chung, Vikas Madan, et al.
Blood Advances|May 30, 2024
Geographic EBV variants confound disease-specific variant interpretation and predict variable immune therapy responsesEdward L Briercheck, Shashidhar Ravishankar, Elshafa Hassan Ahmed, et al.
Blood|October 15, 2021
A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomasAlison J Moskowitz, Paola Ghione, Eric Jacobsen, et al.
Pageof 18

Showing results (141-150 of 172) with videos related to

Sort By:
Pageof 18
Nature Medicine|December 9, 2014
Mutations in G protein β subunits promote transformation and kinase inhibitor resistanceAkinori Yoda, Guillaume Adelmant, Jerome Tamburini, et al.
Genes & Development|March 18, 2022
A distinct core regulatory module enforces oncogene expression in KMT2A-rearranged leukemiaTaku Harada, Yaser Heshmati, Jérémie Kalfon, et al.
Nature Cancer|September 18, 2023
PD-1 instructs a tumor-suppressive metabolic program that restricts glycolysis and restrains AP-1 activity in T cell lymphomaTim Wartewig, Jay Daniels, Miriam Schulz, et al.
The Journal of Experimental Medicine|January 25, 2012
Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibitionOliver Weigert, Andrew A Lane, Liat Bird, et al.
Blood Advances|March 19, 2026
Live-cell Pick-Seq (LiP-Seq): Interrogating ultra-rare mantle cell lymphoma persistent cells after CART19 therapyRan Xu, Gongwei Wu, Siobhan Rice, et al.
Science Translational Medicine|June 28, 2023
Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphomaCristina Mastini, Marco Campisi, Enrico Patrucco, et al.
Plos One|July 5, 2013
Gauging NOTCH1 Activation in Cancer Using ImmunohistochemistryMichael J Kluk, Todd Ashworth, Hongfang Wang, et al.
Cancer Discovery|October 7, 2021
Sex-Biased <i>ZRSR2</i> Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and ApoptosisKatsuhiro Togami, Sun Sook Chung, Vikas Madan, et al.
Blood Advances|May 30, 2024
Geographic EBV variants confound disease-specific variant interpretation and predict variable immune therapy responsesEdward L Briercheck, Shashidhar Ravishankar, Elshafa Hassan Ahmed, et al.
Blood|October 15, 2021
A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomasAlison J Moskowitz, Paola Ghione, Eric Jacobsen, et al.
Pageof 18